Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_4
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients

NCT06209268
completedphase_4

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

NCT00537979
completedphase_4

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

NCT00053547

Clinical Trials (3)

Showing 3 of 3 trials
NCT06209268Not Applicable

The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients

Not Yet Recruiting
NCT00537979Phase 4

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Completed
NCT00053547Phase 4

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3